Abolon was the exclusive advisor to the shareholders of THIS AG on its sale to Rayner, a global leader in products for cataract surgery, headquartered in the UK. The acquisition closed today, 17th January 2024. It was agreed not to disclose the purchase price. Rayner announced today that it has entered into a definitive agreement to acquire Swiss-based THIS AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Sophi (Swiss Ophthalmology Innovation) is an innovative phaco technology providing mobility, simplicity, and safety within the operating theatre. With advanced features including triple pump fluidics, active IOP control, clean venturi and day cassette, cable free power supply and wireless communication, Sophi presents a truly advanced surgical system. The acquisition will enhance Rayner’s breadth of high-quality products for cataract surgery, enabling provision of a full offering also encompassing IOLs, OVDs, eye drops, pharmaceuticals, digital tools, and single-use recyclable instruments.
The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.
The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products
Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.
We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.
Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.